- Company's Quality Commitment Continues
- Undisrupted Distribution of CE Marked Products in European Union
IRVING, Texas, Nov. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that the Company has completed its annual ISO 9001:2000 re-certification inspection at its Irving, Texas location. The inspection was performed by the European Union's notified body, AMTAC Certification Services, Ltd., a division of Intertek Systems Certification. Earlier in 2007, Carrington's wholly-owned subsidiary in Costa Rica, Sabila Industrial, completed its ISO 9001:2000 re-certification inspection.
Dr. Carlton Turner, president and CEO, stated, "Carrington invests a great amount of resources to ensure its quality standards are upheld. Our quality teams in the U.S. and Costa Rica continue to focus on maintaining and improving the Company's quality systems, which defines the standards of all of our raw materials and finished products.
Sabila Industrial manufactures GelSite(R) polymer, the raw material key to the drug and vaccine delivery technology being developed by Carrington's biotech subsidiary DelSite Biotechnologies, Inc. GelSite(R) is the key polymer to formulate the GelVac(TM) influenza nasal powder vaccine for bird flu (H5N1).
Turner continued, "DelSite's vaccine program and working relations with other bio and pharma companies is based on quality in our manufacturing and development areas. Having all formulations and products developed in an ISO facility and under cGMPs provides a solid foundation for future growth of DelSite and our core business."
Carrington's international customer base includes companies who distribute Carrington products in areas of countries such as Italy, France, Portugal, Serbia-Montenegro; with the expansion into countries such as Cypress, Poland and Turkey.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.
|SOURCE Carrington Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved